CalciMedica Inc., a clinical-stage biopharmaceutical company, has announced the publication of a manuscript in the American Journal of Nephrology regarding the design and rationale of the Phase 2 KOURAGE trial of their lead candidate, Auxora™. This trial targets acute kidney injury (AKI) with respiratory failure. The publication includes preclinical data from AKI models and a post-hoc analysis from the Phase 2 CARDEA trial involving patients with severe COVID-19 pneumonia and AKI. Results from these studies indicated a significant increase in glomerular filtration rate and reduced mortality in Auxora-treated subjects. The KOURAGE trial will focus on patients with AKI and respiratory failure, with the primary endpoint being the number of days patients are alive without requiring a ventilator or dialysis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.